p16在胆管癌相关疾病中的表达  

Expression of p16 in cholangiocarcinoma-related diseases

作　　者：林飞峰[1] 金俊哲[1] 

机构地区：[1]中国医科大学附属第四医院肝胆胰外科,沈阳110032

出　　处：《中华肝胆外科杂志》2010年第11期895-896,共2页Chinese Journal of Hepatobiliary Surgery

摘　　要：MTS1／p16基因的突变和缺失在人类多种肿瘤组织中广泛存在。近年来的研究发现p16在胆管癌的形成及发展中发挥着重要作用，在胆管癌相关疾病中也普遍出现p16的异常表达，表明p16与胆管癌关系密切。目前胆管癌的早期诊断率尚低。p16有可能成为一个具有高诊断价值的定性、定量肿瘤标记物，并且为一些新的治疗方法如靶向治疗技术提供机会，实现早期诊断早期治疗的目的，从而提高病人的生存率。The mutations and deletions of the MTS1/ p16 gene are widespread in a variety of human tumor tissues. It has been shown that p16 plays an important role in the formation and development of cholangiocarcinoma as research on cholangiocarcinoma has progressed over the years, and it is thought that the abnormai expression of p16 in highly in- volved in cholangiocarcinoma related diseases. All these findings indicate that p16 is closely related to cholangiocarci noma. Early diagnosis of cholangiocarcinoma is still poor, so p16 may be a qualitative and quantitative tumor marker of high diagnostic value and may provide an opportunity for some new therapeutic methods such as targeted therapy. It can achieve the purpose of early diagnosis and early treatment to enhance the survival rate of patients.

关 键 词：胆管癌 肿瘤抑制基因 

分 类 号：R686[医药卫生—骨科学]